Imatinib is a highly effective therapy for chronic phase-chronic myeloid leukaemia (CP-CML) patients; however, responses to frontline imatinib are variable. The human organic cation transporter 1 ...
Phase 1 trial of 17-AAG in patients with relapsed and refractory multiple myeloma (MM) No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2005 ASCO Annual ...
The malignant phenotype of chronic myeloid leukemia (CML) is due to the abnormal tyrosine kinase activity of the BCR-ABL oncoprotein, which signals several downstream cell survival pathways, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback